EUVIMEDEUVIMED entdecken
Crossref

Impact of Premedication De-Escalation on Incidence of Infusion-Related Reactions With Daratumumab

Donna Vazirnia iD, Alejandro Del Rio Verduzco iD, Scott A Soefje iD, Kristyn A Sanders, Tyler B Sandahl iD

JCO Oncology Practice · 2026-06 · 22 (6) · 1049-1055

DOI: 10.1200/op.23.00470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2026-06. Verfasst von Donna Vazirnia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Arizona, Phoenix, AZ. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Premedication, Multiple Myeloma, Injection Site Reaction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Daratumumab is an anti-CD38 monoclonal antibody used to treat multiple myeloma and light chain amyloidosis. Because daratumumab may cause reactions after intravenous or subcutaneous (SC) administration, the manufacturer labeling recommends administration of premedications before every dose. Given incidence of infusion reactions appears to be rare after cycle 1, in April 2022, the Mayo Clinic implemented a practice change in which premedications were omitted from all daratumumab order sets after completion of cycle 1. This study investigated the safety of this practice. METHODS A retrospective chart review at the Mayo Clinic reviewed eligible patients with multiple myeloma or amyloid light-chain (AL) amyloidosis who received their first dose of daratumumab within the 4 months preceding the date of implementation (preimplementation group) or no more than 4 months after (postimplementation group) the date of implementation on April 13, 2022. Data were collected only from the first eight once per week doses of daratumumab. The primary outcome was the incidence of infusion-related reactions. Data analyzed used descriptive statistics. RESULTS Nearly all patients (95.9%) received daratumumab by SC route of administration. Of the 97 patients in the preimplementation group, >90% received premedications throughout cycles 1 and 2, and five patients (5.2%) experienced infusion reactions. Of 72 patients in the postimplementation group,

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalPremedicationMultiple MyelomaInjection Site ReactionHumansRetrospective StudiesFemaleMaleIncidenceAgedMiddle AgedInfusions, IntravenousAged, 80 and over

Substanzen

daratumumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Mayo Clinic Arizona, Phoenix, AZ.
  • Mayo Clinic Healthcare System-Eau Claire, Eau Claire, WI.
  • Mayo Clinic Rochester, Rochester, MN.

ORCID-Profile: Donna Vazirnia, Alejandro Del Rio Verduzco, Scott A Soefje, Tyler B Sandahl

Zitieren

APA

Vazirnia, D., Del Rio Verduzco, A., Soefje, S. A., Sanders, K. A., & Sandahl, T. B. (2026). Impact of Premedication De-Escalation on Incidence of Infusion-Related Reactions With Daratumumab. JCO Oncology Practice, 22(6), 1049-1055. https://doi.org/10.1200/op.23.00470

Vancouver

Vazirnia D, Del Rio Verduzco A, Soefje SA, Sanders KA, Sandahl TB. Impact of Premedication De-Escalation on Incidence of Infusion-Related Reactions With Daratumumab. JCO Oncology Practice. 2026;22(6):1049-1055. doi:10.1200/op.23.00470

BibTeX
@article{Vazirnia2026,
  author = {Vazirnia, Donna and Del Rio Verduzco, Alejandro and Soefje, Scott A and Sanders, Kristyn A and Sandahl, Tyler B},
  title = {Impact of Premedication De-Escalation on Incidence of Infusion-Related Reactions With Daratumumab},
  journal = {JCO Oncology Practice},
  year = {2026},
  volume = {22},
  number = {6},
  pages = {1049--1055},
  doi = {10.1200/op.23.00470}
}
Kostenlos starten →